Risk Stratification of Endometrial Cancer Patients: FIGO Stage, Biomarkers and Molecular Classification
暂无分享,去创建一个
F. Amant | G. Kristensen | K. Lindemann | J. Pijnenborg | C. Krakstad | J. Kasius | D. Forsse | H. M. Werner | Judith van Zwol | Henrica M. J. Werner
[1] G. Ortoft,et al. Predictive value of the new ESGO-ESTRO-ESP endometrial cancer risk classification on survival and recurrence in the Danish population , 2021, International Journal of Gynecological Cancer.
[2] J. How,et al. Sentinel lymph node biopsy in high-grade endometrial cancer: a systematic review and meta-analysis of performance characteristics. , 2021, American journal of obstetrics and gynecology.
[3] G. Zannoni,et al. New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines , 2021, Cancers.
[4] F. Amant,et al. Incorporating molecular profiling into endometrial cancer management requires prospective studies , 2021, International Journal of Gynecological Cancer.
[5] L. Havrilesky,et al. Primary cytoreductive surgery for advanced stage endometrial cancer: A systematic review and meta-analysis. , 2021, American journal of obstetrics and gynecology.
[6] L. Alexandrov,et al. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] M. Mueller,et al. Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer , 2021, medRxiv.
[8] L. Insabato,et al. Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer , 2021, Archives of Gynecology and Obstetrics.
[9] M. Morgan,et al. Is there a benefit of performing an omentectomy for clinical stage I high-grade endometrial carcinoma? , 2021, Surgical oncology.
[10] D. Levine,et al. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. , 2021, Gynecologic oncology.
[11] A. Jemal,et al. Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.
[12] B. Winkens,et al. Lymphedema and Post-Operative Complications after Sentinel Lymph Node Biopsy versus Lymphadenectomy in Endometrial Carcinomas—A Systematic Review and Meta-Analysis , 2020, Journal of clinical medicine.
[13] H. Mackay,et al. HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes , 2020, Cancers.
[14] Cyrus Chargari,et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma , 2020, International Journal of Gynecological Cancer.
[15] S. Leung,et al. The cut-off for estrogen and progesterone receptor in endometrial cancer revisited: an ENITEC collaboration study. , 2020, Human pathology.
[16] Ho Jin Jung,et al. Interobserver diagnostic reproducibility in advanced-stage endometrial carcinoma , 2020, Journal of pathology and translational medicine.
[17] L. Chambers,et al. Impact of treatment modality on overall survival in women with advanced endometrial cancer: A National Cancer Database analysis. , 2020, Gynecologic oncology.
[18] H. Putter,et al. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer , 2020, International Journal of Gynecological Cancer.
[19] P. Lin,et al. MET Mutation Is a Potential Therapeutic Target for Advanced Endometrial Cancer , 2020, Cancers.
[20] K. Pantel,et al. Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond , 2020, British Journal of Cancer.
[21] A. Tinker,et al. LBA36 Safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): Results from GARNET , 2020 .
[22] M. Schlumbrecht,et al. Thrombocytosis as a Biomarker in Type II, Non-Endometrioid Endometrial Cancer , 2020, Cancers.
[23] H. Putter,et al. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] P. Harter,et al. Malignant peritoneal cytology and increased mortality risk in stage I non-endometrioid endometrial cancer. , 2020, Gynecologic oncology.
[25] G. Dittmar,et al. Prognostic Biomarkers in Endometrial Cancer: A Systematic Review and Meta-Analysis , 2020, Journal of clinical medicine.
[26] F. Guyon,et al. Combined pelvic and para-aortic is superior to only pelvic lymphadenectomy in intermediate and high-risk endometrial cancer: a systematic review and meta-analysis , 2020, Archives of Gynecology and Obstetrics.
[27] D. Boll,et al. Impact of different adjuvant treatment approaches on survival in stage III endometrial cancer: A population-based study. , 2020, European journal of cancer.
[28] Peter J.F. Lucas,et al. Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study , 2020, PLoS medicine.
[29] D. Boll,et al. Incidence and predictors of peritoneal metastases of gynecological origin: a population-based study in the Netherlands , 2020, Journal of gynecologic oncology.
[30] E. Moss,et al. Utility of Circulating Tumor DNA for Detection and Monitoring of Endometrial Cancer Recurrence and Progression , 2020, Cancers.
[31] Julie A. Dybvik,et al. Preoperative 18F-FDG PET/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer , 2020, European Radiology.
[32] M. C. Vos,et al. Molecular profiling identifies synchronous endometrial and ovarian cancers as metastatic endometrial cancer with favorable clinical outcome , 2020, International journal of cancer.
[33] C. Moiola,et al. Genomic Profiling of Uterine Aspirates and cfDNA as an Integrative Liquid Biopsy Strategy in Endometrial Cancer , 2020, Journal of clinical medicine.
[34] T. Bosse,et al. Incorporation of molecular characteristics into endometrial cancer management , 2019, Histopathology.
[35] C. Gilks,et al. Clinicopathological and molecular characterisation of ‘multiple‐classifier’ endometrial carcinomas , 2019, The Journal of pathology.
[36] J. Lang,et al. The prognostic role of peritoneal cytology in stage IA endometrial endometrioid carcinomas. , 2019, Current problems in cancer.
[37] M. Guida,et al. TCGA molecular groups of endometrial cancer: Pooled data about prognosis. , 2019, Gynecologic oncology.
[38] M. Stockler,et al. Updated results of activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601) , 2019, Annals of Oncology.
[39] H. Putter,et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial , 2019, The Lancet. Oncology.
[40] S. Bandyopadhyay,et al. Molecular classification of endometrial carcinoma applied to endometrial biopsy specimens: Towards early personalized patient management. , 2019, Gynecologic oncology.
[41] J. McAlpine,et al. Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer. , 2019, Gynecologic oncology.
[42] W. E. Richards,et al. Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. , 2019, The New England journal of medicine.
[43] L. Massuger,et al. Diagnostic Accuracy of Clinical Biomarkers for Preoperative Prediction of Lymph Node Metastasis in Endometrial Carcinoma: A Systematic Review and Meta-Analysis. , 2019, The oncologist.
[44] B. Weigelt,et al. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer. , 2019, Gynecologic oncology.
[45] C. Høgdall,et al. Lymph-vascular space invasion (LVSI) as a strong and independent predictor for non-locoregional recurrences in endometrial cancer: a Danish Gynecological Cancer Group Study , 2019, Journal of gynecologic oncology.
[46] Jae-Weon Kim,et al. Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] M. Köbel,et al. Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility , 2018, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[48] B. Job,et al. Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas , 2018, Clinical Cancer Research.
[49] A. Talhouk,et al. L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile , 2018, British Journal of Cancer.
[50] P. Pollock,et al. Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative , 2018, Modern Pathology.
[51] M. Köbel,et al. Letter in response to: McAlpine J, Leon‐Castillo A, Bosse T. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. J Pathol 2018; 244: 538–549 , 2018, The Journal of pathology.
[52] A. Talhouk,et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[53] T. Enomoto,et al. Significance of abnormal peritoneal cytology on survival of women with stage I-II endometrioid endometrial cancer. , 2018, Gynecologic oncology.
[54] C. Gilks,et al. Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups , 2018, The American journal of surgical pathology.
[55] J. McAlpine,et al. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses , 2018, The Journal of pathology.
[56] A. Secord,et al. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] Jing Cai,et al. Survival benefits of pelvic lymphadenectomy versus pelvic and para-aortic lymphadenectomy in patients with endometrial cancer , 2018, Medicine.
[58] B. Seagle,et al. Prognosis and treatment of positive peritoneal cytology in early endometrial cancer: matched cohort analyses from the National Cancer Database , 2017, American journal of obstetrics and gynecology.
[59] J. Kelley,et al. Prognostic Significance of omental Disease and the Role of Omental Sampling in Patients With Uterine Carcinosarcoma , 2017, International Journal of Gynecologic Cancer.
[60] A. Bryant,et al. Lymphadenectomy for the management of endometrial cancer. , 2017, The Cochrane database of systematic reviews.
[61] I. Nagtegaal,et al. Accuracy of Endometrial Sampling in Endometrial Carcinoma: A Systematic Review and Meta-analysis. , 2017, Obstetrics and gynecology.
[62] Samuel Leung,et al. Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification , 2017, The journal of pathology. Clinical research.
[63] P. Pollock,et al. Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative. , 2017, Gynecologic oncology.
[64] G. Mills,et al. CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence , 2017, Modern Pathology.
[65] A. Talhouk,et al. Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup , 2017, The American journal of surgical pathology.
[66] X. Sun,et al. Detection of circulating tumour cells may add value in endometrial cancer management. , 2016, European journal of obstetrics, gynecology, and reproductive biology.
[67] D. Tritchler,et al. Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] H. Putter,et al. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. , 2016, The Lancet. Oncology.
[69] D. Timmerman,et al. Evaluation of models to predict lymph node metastasis in endometrial cancer: A multicentre study. , 2016, European journal of cancer.
[70] H. Salvesen,et al. High Diagnostic Value of 18F-FDG PET/CT in Endometrial Cancer: Systematic Review and Meta-Analysis of the Literature , 2016, The Journal of Nuclear Medicine.
[71] H. Putter,et al. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts , 2016, Clinical Cancer Research.
[72] S. Bendifallah,et al. Predictive Modeling: A New Paradigm for Managing Endometrial Cancer , 2016, Annals of Surgical Oncology.
[73] Elena Pereira,et al. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers , 2015, PloS one.
[74] G. Botti,et al. Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients. , 2015, Pharmacogenomics.
[75] A. Talhouk,et al. A clinically applicable molecular-based classification for endometrial cancers , 2015, British Journal of Cancer.
[76] A. Viale,et al. Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas. , 2015, Journal of the National Cancer Institute.
[77] A. Talhouk,et al. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. , 2015, Gynecologic oncology.
[78] P. Schwartz,et al. Microscopic Omental Metastasis in Clinical Stage I Endometrial Cancer: A Meta-analysis , 2015, Annals of Surgical Oncology.
[79] Minetta C. Liu,et al. Detection of circulating tumor cells in high-risk endometrial cancer. , 2015, Anticancer research.
[80] H. Chung,et al. Peritoneal cytology: a risk factor of recurrence for non-endometrioid endometrial cancer. , 2014, Gynecologic oncology.
[81] B. Weigelt,et al. Classification of endometrial carcinoma: more than two types. , 2014, The Lancet. Oncology.
[82] Ulla-Maija Haltia,et al. FIGO 1988 versus 2009 staging for endometrial carcinoma: a comparative study on prediction of survival and stage distribution according to histologic subtype , 2014, Journal of gynecologic oncology.
[83] J. Marcickiewicz,et al. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. , 2013, European journal of cancer.
[84] A. Romano,et al. Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer , 2013, Molecular Cancer.
[85] P. Altevogt,et al. L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. , 2013, Journal of the National Cancer Institute.
[86] C Blake Gilks,et al. Poor Interobserver Reproducibility in the Diagnosis of High-grade Endometrial Carcinoma , 2013, The American journal of surgical pathology.
[87] Steven J. M. Jones,et al. Integrated genomic characterization of endometrial carcinoma , 2013, Nature.
[88] N. Hacker,et al. Data Set for Reporting of Endometrial Carcinomas: Recommendations From the International Collaboration on Cancer Reporting (ICCR) Between United Kingdom, United States, Canada, and Australasia , 2013, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[89] E. Pirog,et al. The Diagnosis of Endometrial Carcinomas With Clear Cells by Gynecologic Pathologists: An Assessment of Interobserver Variability and Associated Morphologic Features , 2012, The American journal of surgical pathology.
[90] H. Chung,et al. Preoperative identification of a low-risk group for lymph node metastasis in endometrial cancer: a Korean gynecologic oncology group study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] R. Rouzier,et al. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). , 2011, The Lancet. Oncology.
[92] R. Naumann. The role of lymphadenectomy in endometrial cancer: was the ASTEC trial doomed by design and are we destined to repeat that mistake? , 2011, Gynecologic oncology.
[93] P. Zola,et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. , 2010, European journal of cancer.
[94] R. Bristow,et al. Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. , 2010, Gynecologic oncology.
[95] T. Herzog,et al. ASTEC lymphadenectomy and radiation therapy studies: are conclusions valid? , 2010, Gynecologic oncology.
[96] P. Gehrig,et al. Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. , 2009, Gynecologic oncology.
[97] V. Torri,et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. , 2009, Journal of the National Cancer Institute.
[98] A. Olawaiye,et al. Management of women with clear cell endometrial cancer: a Society of Gynecologic Oncology (SGO) review. , 2009, Gynecologic oncology.
[99] S. Pecorelli. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium , 2009 .
[100] M. Parmar,et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study , 2009, The Lancet.
[101] N. Eritja,et al. Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints , 2008, Journal of Clinical Pathology.
[102] H. Watari,et al. A validation study of a scoring system to estimate the risk of lymph node metastasis for patients with endometrial cancer for tailoring the indication of lymphadenectomy. , 2007, Gynecologic oncology.
[103] A. Berchuck,et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[104] J. McAlpine,et al. Upstaging based solely on positive peritoneal washing does not affect outcome in endometrial cancer , 2005, Modern Pathology.
[105] S. Kalloger,et al. Description of a Novel System for Grading of Endometrial Carcinoma and Comparison With Existing Grading Systems , 2005, The American journal of surgical pathology.
[106] H. Verkooijen,et al. Positive peritoneal cytology in early-stage endometrial cancer does not influence prognosis , 2004, British Journal of Cancer.
[107] W. McCluggage,et al. A Critical Appraisal of the Value of Immunohistochemistry in Diagnosis of Uterine Neoplasms , 2004, Advances in anatomic pathology.
[108] W. van Putten,et al. Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma , 2004, Cancer.
[109] R. Kurman,et al. A Binary Architectural Grading System for Uterine Endometrial Endometrioid Carcinoma Has Superior Reproducibility Compared With FIGO Grading and Identifies Subsets of Advance-Stage Tumors With Favorable and Unfavorable Prognosis , 2000, The American journal of surgical pathology.
[110] M. J. Webb,et al. Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? , 2000, American journal of obstetrics and gynecology.
[111] D. O'connor,et al. An analysis of two versus three grades for endometrial carcinoma. , 1999, Gynecologic oncology.
[112] J. Shepherd,et al. FIGO staging of gynecologic cancer , 1999 .
[113] J. V. Bokhman. Two pathogenetic types of endometrial carcinoma. , 1983, Gynecologic oncology.
[114] P. Disaia,et al. Adenocarcinoma of the endometrium: its metastatic lymph node potential. A preliminary report. , 1976, Gynecologic oncology.
[115] J. Thigpen,et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[116] Hornor,et al. Letter & Response. , 2000, Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners.
[117] J. Shepherd,et al. FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. , 1999, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[118] C. Holinka,et al. Endometrial carcinoma: two diseases? , 1987, Cancer detection and prevention.
[119] S. Leung,et al. The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study , 2022, Human Pathology.